TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
RARE

Ultragenyx

Healthcare · Biotechnology

14.90$ -4.7% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

Ultragenyx (RARE) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Total Assets" came in at 1,532 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RARE
Line item 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
12 88 60 198 560 541 491 720 1,135 1,760 1,522 1,545 1,491 1,503 1,532
11 86 55 187 450 498 244 522 851 1,295 857 884 732 817 951
11 86 7.4 24 94 161 100 113 434 714 308 133 214 174 434
11 86 53 187 437 498 244 460 755 1,202 740 748 577 610 693
0.1 – – – – – 5.2 13 33 23 44 40 73 122 159
– – – 0.0 0.0 0.0 0.8 7.1 12 13 16 27 34 45 52
0.8 1.4 1.3 3.0 7.4 17 22 20 75 74 141 260 – – –
– – – 0.0 0.0 0.0 44 44 44 44 44 44 44 44 44
– – – 0.0 0.0 0.0 142 129 129 131 131 160 166 178 176
1.5 4.0 9.5 13 28 67 107 111 482 605 600 1,193 1,216 1,241 1,605
1.0 3.2 5.9 13 28 60 71 75 103 190 181 261 280 344 384
– – – – – – – – 7.2 9.0 11 12 13 10 81
0.3 1.2 1.4 4.9 2.9 5.4 8.9 12 13 13 17 43 42 39 31
0.2 0.5 3.4 0.0 0.0 0.0 0.0 – – – – – – – –
11 84 50 185 531 474 383 609 654 1,154 923 352 275 255 -80
-8.2 -27 -75 -139 -285 -531 -833 -1,030 -1,433 -1,620 -2,074 -2,781 -3,388 -3,957 -4,532
23 23 29 29 37 40 42 50 57 61 68 70 74 91 99

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?